About Azora Therapeutics
Azora Therapeutics is a company based in Los Angeles (United States) founded in 2019 by Matt Davidson was acquired by Adial Pharmaceuticals in June 2026. Azora Therapeutics has raised $581.45 thousand across 1 funding round from investors including Adial Pharmaceuticals. Azora Therapeutics offers products and services including AT177 and AT193. Azora Therapeutics operates in a competitive market with competitors including Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.
- Headquarter Los Angeles, United States
- Founders Matt Davidson
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Azora Therapeutics Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$581.45 K (USD)
in 1 rounds
-
Latest Funding Round
$581.45 K (USD), Seed
Aug 08, 2023
- Investors
-
Employee Count
Not available
-
Acquired by
Adial Pharmaceuticals
(Jun 11, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Azora Therapeutics
Azora Therapeutics offers a comprehensive portfolio of products and services, including AT177 and AT193.
Investigational small molecule for autoimmune diseases treatment
Investigational therapy for serious inflammatory conditions
People of Azora Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Azora Therapeutics
Azora Therapeutics has successfully raised a total of $581.45K through 1 strategic funding round. The most recent funding activity was a Seed round of $581.45 thousand completed in August 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Azora Therapeutics
Azora Therapeutics has secured backing from 1 investor. Prominent investors backing the company include Adial Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Therapeutics for addiction treatment are developed by Adial Pharmaceuticals.
|
Locked | Locked | Locked |
Investor details for Azora Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Azora Therapeutics
Investment portfolio details for Azora Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Azora Therapeutics
Detailed financials for Azora Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Azora Therapeutics Comparisons
Peer comparison for Azora Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Azora Therapeutics
Azora Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| Locked | Locked | Locked |
GPCR drug discovery platform is developed for multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for allergic and inflammatory diseases are developed.
|
Detailed competitors of Azora Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Azora Therapeutics
Complete news archive for Azora Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Azora Therapeutics
Azora Therapeutics was founded in 2019 and raised its 1st funding round 4 years after it was founded.
Azora Therapeutics is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
Matt Davidson is the current CEO of Azora Therapeutics. They have also founded this company.
Azora Therapeutics is a funded company, having raised a total of $581.45K across 1 funding round to date.
Azora Therapeutics was founded in 2019 in Los Angeles, United States, within the biotechnology sector. Small molecule formulations are developed to activate the AhR pathway in the skin and colon, aiming to modulate immune responses for inflammatory conditions. Operations center on advancing treatments for diseases such as Hidradenitis Suppurativa, nail psoriasis, and ulcerative colitis, with AT-193 as the primary candidate under evaluation.
Azora Therapeutics's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.
Azora Therapeutics offers AT177 and AT193.
Azora Therapeutics has 1 investor. Key investors include Adial Pharmaceuticals.